iSpecimen Inc. Increase (Decrease) in Accounts Receivable
iSpecimen Inc. (ISPC) reported Increase (Decrease) in Accounts Receivable of -$30.62 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-14
- iSpecimen Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$115.54K.
- iSpecimen Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $84.92K.
- iSpecimen Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$26.83K, a 105.94% decline year-over-year.
- iSpecimen Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$255.06K, a 407.96% decline year-over-year.
- iSpecimen Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$1.34M, a 247.95% decline from fiscal 2024.
- iSpecimen Inc. increase (decrease) in accounts receivable for fiscal 2024 was $903.33K.
- iSpecimen Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$564.49K.
- iSpecimen Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$1.30M, a 179.28% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$115.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$30.62K 10-Q · filed 2026-08-14 | -$57.45K derived: sum of 3 quarters · filed 2026-08-14 | -$312.50K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $84.92K 10-Q · filed 2026-05-18 | $58.09K derived: sum of 2 quarters · filed 2026-05-18 | -$196.97K derived: sum of 3 quarters · filed 2026-05-18 | -$499.61K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$26.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$281.89K derived: sum of 2 quarters · filed 2026-04-01 | -$584.53K derived: sum of 3 quarters · filed 2026-08-14 | -$1.34M 10-K · filed 2026-04-01 |
| 2025-09-30 | -$255.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$557.71K derived: sum of 2 quarters · filed 2026-08-14 | -$1.31M 10-Q · filed 2025-11-17 | -$858.08K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$302.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.05M 10-Q · filed 2026-08-14 | -$603.02K derived: sum of 3 quarters · filed 2026-08-14 | -$520.20K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$751.94K 10-Q · filed 2026-05-18 | -$300.37K derived: sum of 2 quarters · filed 2026-05-18 | -$217.55K derived: sum of 3 quarters · filed 2026-05-18 | $244.43K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $451.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $534.39K derived: sum of 2 quarters · filed 2026-04-01 | $996.37K derived: sum of 3 quarters · filed 2026-04-01 | $903.33K 10-K · filed 2026-04-01 |
| 2024-09-30 | $82.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $544.80K derived: sum of 2 quarters · filed 2025-11-17 | $451.76K 10-Q · filed 2025-11-17 | -$463.51K derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $461.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $368.94K 10-Q · filed 2025-08-14 | -$546.33K derived: sum of 3 quarters · filed 2025-08-14 | -$318.09K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$93.04K 10-Q · filed 2025-05-19 | -$1.01M derived: sum of 2 quarters · filed 2025-05-19 | -$780.07K derived: sum of 3 quarters · filed 2025-05-19 | -$2.22M derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | -$915.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | -$687.03K derived: sum of 2 quarters · filed 2025-04-14 | -$2.13M derived: sum of 3 quarters · filed 2025-04-14 | -$564.49K 10-K · filed 2025-04-14 |
| 2023-09-30 | $228.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.21M derived: sum of 2 quarters · filed 2024-11-07 | $350.78K 10-Q · filed 2024-11-07 | -$519.37K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $122.54K 10-Q · filed 2024-08-06 | -$747.61K derived: sum of 3 quarters · filed 2024-08-06 | -$102.69K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.56M 10-Q · filed 2024-05-07 | $690.56K derived: sum of 2 quarters · filed 2024-05-07 | $1.34M derived: sum of 3 quarters · filed 2024-05-07 | $743.42K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$870.15K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$225.22K derived: sum of 2 quarters · filed 2024-03-13 | -$817.29K derived: sum of 3 quarters · filed 2024-03-13 | -$1.30M 10-K · filed 2024-03-13 |
| 2022-09-30 | $644.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $52.86K derived: sum of 2 quarters · filed 2023-11-02 | -$427.80K 10-Q · filed 2023-11-02 | -$16.82K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$592.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$1.07M 10-Q · filed 2023-08-02 | -$661.74K derived: sum of 3 quarters · filed 2023-08-02 | $64.06K derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | -$480.66K 10-Q · filed 2023-05-04 | -$69.68K derived: sum of 2 quarters · filed 2023-05-04 | $656.13K derived: sum of 3 quarters · filed 2023-05-04 | $2.08M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $410.98K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $1.14M derived: sum of 2 quarters · filed 2023-03-30 | $2.56M derived: sum of 3 quarters · filed 2023-03-30 | $1.64M 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $725.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.15M derived: sum of 2 quarters · filed 2022-11-08 | $1.23M 10-Q · filed 2022-11-08 | $1.10M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $500.34K 10-Q · filed 2022-08-04 | $376.42K derived: sum of 3 quarters · filed 2022-08-04 | $1.12M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$925.54K 10-Q · filed 2022-05-10 | -$1.05M derived: sum of 2 quarters · filed 2022-05-10 | -$307.75K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$123.92K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $617.79K derived: sum of 2 quarters · filed 2022-03-22 | $800.91K 10-K · filed 2022-03-22 | |
| 2020-09-30 | $741.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $924.83K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $183.12K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |